71 reports

  • Vendor landscape
  • ASTRAZENECA

These agents are associated with reduced rates of hypoglycemia, moderate and continuous weight loss, and gastrointestinal side effects such as nausea and vomiting.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • 9 Appendix

GASTROINTESTINAL EVENTS SUCH AS NAUSEA AND DIARRHEA OCCURRED MOST FREQUENTLY.

  • Type 2 Diabetes
  • Asia
  • World
  • Novo Nordisk Group
  • Sanofi S.A.

The company' s major therapeutic areas INCLUDE IMMUNOLOGY, CVD, DIABETES, GASTROINTESTINAL DISEASE, INFECTIOUS DISEASES, MUSCULOSKELETAL DISEASE, NEUROSCIENCE, ONCOLOGY, OPHTHALMOLOGY, AND RESPIRATORY DISEASES.

  • Type 2 Diabetes
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • 7.1 OVERVIEW

DESPITE ITS LOW COST, GASTROINTESTINAL (GI) SIDE EFFECTS ARE VERY COMMON WITH ACARBOSE, WHICH HAS PREVENTED ITS WIDESPREAD USE.

  • Type 2 Diabetes
  • Europe
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

THE ENDOBARRIER GASTROINTESTINAL LINER IS TRANSORALLY PLACED IN THE GASTROINTESTINAL TRACT IN ORDER TO BYPASS A PORTION OF THE INTESTINE.

  • Type 2 Diabetes
  • United States
  • EnteroMedics Inc.
  • Novo Nordisk Group
  • VIVUS, Inc.

Gastrointestinal complications of diabetes.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Europe
  • Trial Results

GASTROINTESTINAL, AUTOIMMUNE DISEASE HISTORY OF MALIGNANCY, DRUG OR ALCOHOL ABUSE PARTICIPATION IN ANY PREVIOUS TRIAL ON ACE INHIBITOR TAKING OTHER INVESTIGATIONAL DRUGS WITHIN THE PAST ## DAYS KNOWN HISTORY OF SENSITIVITY / ALLERGY TO ACE INHIBITOR EXPECTED SURVIVAL LESS THAN ## YEARS

  • Type 2 Diabetes
  • World
  • Anthera Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Novartis AG

PATIENTS IN THE STANDARD CARE GROUP DEVELOPED CELLULITIS OF THE EFFECTED EXTREMITY (TWO PATIENTS), A GASTROINTESTINAL BLEED (ONE PATIENT), AND ACUTE PYELONEPHRITIS (ONE PATIENT).

  • Type 2 Diabetes
  • Japan
  • FirstString Research, Inc.
  • Organogenesis, Inc.
  • Smith & Nephew Plc

The combined portfolio of the two companies includes drugs in areas of dermatology, CNS, eye care, women' s health, urology, gastrointestinal, cystic fibrosis, cardiovascular, and infectious diseases.

  • Type 2 Diabetes
  • Actavis plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG

WE ARE ALSO ACTIVE IN THE INFECTION, NEUROSCIENCE AND GASTROINTESTINAL (ING) DISEASE AREAS.

  • Type 2 Diabetes
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.

IBD is a chronic, recurring disease of the gastrointestinal tract, afflicts over ##. ## million people in the U. S and current therapies are only modestly successful with significant adverse side effects, including immune suppression and malignancies.

  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative
  • BioTherapeutics Inc.

WE ARE ALSO ACTIVE IN THE INFECTION, NEUROSCIENCE AND GASTROINTESTINAL (ING) DISEASE AREAS.

  • Type 2 Diabetes
  • United States
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Pipeline by Ardelyx Inc, H1 2018
  • Pipeline by Intercept Pharmaceuticals Inc, H1 2018

The drug candidate is an agonist of TGR##, a G protein-coupled receptor found in the gastrointestinal (GI) tract.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative
  • PIPELINE BY ELI LILLY AND COMPANY, H2 2017

Hanmi Pharma" s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative

GPR## is expressed at high concentrations in the pancreas and gastrointestinal tract.

  • Molecular Diagnostic
  • Pharmaceutical
  • Type 2 Diabetes
  • World
  • Product Initiative
  • RDX-98940 - Drug Profile
  • Pipeline by Ardelyx Inc, H2 2017

The drug candidate is an agonist of TGR##, a G protein-coupled receptor found in the gastrointestinal (GI) tract.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative
  • PIPELINE BY ELI LILLY AND CO, H1 2018

Hanmi Pharma' s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative
  • SMALL MOLECULE TO INHIBIT IKK AND TBK1 FOR CARDIOVASCULAR, GASTROINTESTINAL AND METABOLIC DISORDERS - DRUG PROFILE
  • OBESITY - PIPELINE BY BIORESTORATIVE THERAPIES INC, H1 2017
  • Diabetes
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative
  • SAR-425899 - DRUG PROFILE

The patients enrolled in the trial experienced mild to moderate gastrointestinal adverse events at some point.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • RDX-98940 - DRUG PROFILE

THE DRUG CANDIDATE IS AN AGONIST OF TGR##, A G PROTEIN-COUPLED RECEPTOR FOUND IN THE GASTROINTESTINAL (GI) TRACT.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative

Hyperglycemia - Pipeline Review, H## 2017 Reference Code: GMDHC##IDB Publication Date: June 2017 Introduction Global Markets Direct Report Coverage Global Markets Direct' s, ' Hyperglycemia - Pipeline Review, H## 2017', provides an overview of the Hyperglycemia pipeline landscape.

  • Pharmaceutical
  • Type 2 Diabetes
  • World
  • Product Initiative
  • Mitsubishi Corporation

Gastrointestinal disorders were most commonly observed adverse events.

  • Diabetes
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • Omeros Corporation

GPR## is expressed at high concentrations in the pancreas and gastrointestinal tract.

  • Molecular Diagnostic
  • Pharmaceutical
  • Type 2 Diabetes
  • World
  • Product Initiative

Pharmaceuticals & Healthcare - Deals and Alliances Profile Poxel SA (POXEL) October 2017 Report Code: GDPH##D Published: Company Snapshot Company Overview Key Facts Poxel SA (Poxel) is a biopharmaceutical company that develops and markets drugs for metabolic diseases.

  • Diabetes
  • Type 2 Diabetes
  • Japan
  • Company
  • POXEL SA
  • APR 02, 2016: SEMAGLUTIDE DEMONSTRATED SUPERIOR IMPROVEMENTS IN GLYCAEMIC CONTROL VS PLACEBO IN ADULTS WITH TYPE 2 DIABETES
  • 09/15/2016: VICTOZA LOWERED THE PROGRESSION OF KIDNEY DAMAGE IN ADULTS WITH TYPE 2 DIABETES AT HIGH CV RISK

The most common adverse events leading to the discontinuation of Victoza® were gastrointestinal events.

  • Diabetes
  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Novo Nordisk Group
  • Deal Information Deal Status Completed Date Deal Financials
  • Jun 19, 2017: GI Dynamics Announces Additional Members to Its Scientific Advisory Board

His clinical areas of expertise include laparoscopic and gastrointestinal surgery.

  • Healthcare
  • Type 2 Diabetes
  • United States
  • Company
  • GI Dynamics

Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Genito Urinary System And Sex Hormones, Gastrointestinal, Immunology, Oncology, Respiratory and Undisclosed which include indications Diabetic Complications, Diabetic Nephropathy, Acute Ischemic Stroke, Atheroscl

  • Chronic Disease
  • Diabetes
  • Therapy
  • Type 2 Diabetes
  • GenKyoTex S.A.
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY GILEAD SCIENCES INC, H2 2017
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY GNI GROUP LTD, H2 2017

No grade ## gastrointestinal adverse events were reported.

  • Chronic Disease
  • Genitourinary System Disease
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • TYPE 2 DIABETES - PIPELINE BY SERES THERAPEUTICS INC, H2 2017
  • R&D Progress
  • Biopharmaceutical
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative
  • JAN 21, 2016: VTV THERAPEUTICS INITIATES PHASE 2 TRIAL EVALUATING TTP273 FOR THE TREATMENT OF TYPE 2 DIABETES

In this study, all doses of TTP## were well tolerated with no serious adverse events or evidence of significant gastrointestinal side effects.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company Operations
  • vTv Therapeutics LLC